Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

UBS Warburg Cuts Cytyc to 'Hold'


UBS Warburg cut Cytyc (CYTC) to hold from buy.

Analyst Ricky Goldwasser says her downgrade reflects a change in the competitive environment for cervical cancer screening. She notes Roche acquired a broad HPV (human papillomavirus) patent portfolio from Institute Pasteur. This means Roche can now develop and commercialize screening tests for HPV that compete with a test that Digene owns.

Goldwasser says Roche told her it plans to introduce a test on the market by the end of 2003. She believes the news could put Cytyc's planned acquisition of Digene at risk. She cut her $23 target to $19.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus